These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
78 related articles for article (PubMed ID: 18338434)
21. Analysis of a switch from enfuvirtide to raltegravir in patients with undetectable viral load: efficacy and quality of life at 24 weeks. Sayana S; Prosser P; Ricaurte JC; Sanchez S; Hamwi G; Hershey-Weber J; Chien C; Easley A; Nguyen T; Wilson L; Khanlou H J Int Assoc Physicians AIDS Care (Chic); 2009; 8(2):85-6. PubMed ID: 19369697 [No Abstract] [Full Text] [Related]
22. [Entry inhibitors. Ring-free for a new principle of action]. Rümmelein N; Jäger H MMW Fortschr Med; 2003 Apr; 145 Spec No 1():16-20. PubMed ID: 15011578 [TBL] [Abstract][Full Text] [Related]
23. Localized amyloidosis at the site of enfuvirtide injection. Morilla ME; Kocher J; Harmaty M Ann Intern Med; 2009 Oct; 151(7):515-6. PubMed ID: 19805777 [No Abstract] [Full Text] [Related]
25. Consensus recommendation from a group of German experts for the use of enfuvirtide in heavily pretreated HIV patients. Salzberger B; Däumer M; Gute P; Jaeger H; Knechten H; van Lunzen J; Mauss S; Mayr C; Moll A; Plettenberg A; Rockstroh J; Staszewski S; Stellbrink HJ; Stoll M; Sturmer M Eur J Med Res; 2007 Mar; 12(3):93-102. PubMed ID: 17507306 [TBL] [Abstract][Full Text] [Related]
26. Initiation of therapy with a subcutaneously administered antiretroviral in treatment-experienced HIV-infected patients: understanding physician and patient perspectives. Horne R; Cooper V; Fisher M AIDS Care; 2008 Oct; 20(9):1029-38. PubMed ID: 18825512 [TBL] [Abstract][Full Text] [Related]
28. [HIV infections: further options for combination therapy]. Hildegard K Dtsch Med Wochenschr; 2003 Jul; 128(28-29):1523. PubMed ID: 12899165 [No Abstract] [Full Text] [Related]
29. Short communication safety, tolerability and pharmacokinetics of enfuvirtide administered by a needle-free injection system compared with subcutaneous injection. Gottlieb M; Thommes JA; Antivir Ther; 2008; 13(5):723-7. PubMed ID: 18771056 [TBL] [Abstract][Full Text] [Related]
35. Use of darunavir and enfuvirtide in a pregnant woman. Sued O; Lattner J; Gun A; Patterson P; Abusamra L; Cesar C; Fink V; Krolewiecki A; Cahn P Int J STD AIDS; 2008 Dec; 19(12):866-7. PubMed ID: 19050223 [TBL] [Abstract][Full Text] [Related]
36. A large prospective study assessing injection site reactions, quality of life and preference in patients using the Biojector vs standard needles for enfuvirtide administration. Loutfy MR; Harris M; Raboud JM; Antoniou T; Kovacs C; Shen S; Dufresne S; Smaill F; Rouleau D; Rachlis A; Gough K; Lalonde R; Tsoukas C; Trottier B; Walmsley SL; Montaner JS HIV Med; 2007 Oct; 8(7):427-32. PubMed ID: 17760734 [TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetics, pharmacodynamics and safety of once-daily versus twice-daily dosing with enfuvirtide in HIV-infected subjects. Thompson M; DeJesus E; Richmond G; Wheeler D; Flaherty J; Piliero P; True A; Chiu YY; Zhang Y; McFalls E; Miralles GD; Patel IH AIDS; 2006 Feb; 20(3):397-404. PubMed ID: 16439873 [TBL] [Abstract][Full Text] [Related]
38. Postmarketing use of enfuvirtide in veterans: provider compliance with criteria for use, overall efficacy, and tolerability. Belperio PS; Mole LA; Halloran J; Boothroyd DB; Thomas IC; Backus LI Ann Pharmacother; 2008 Nov; 42(11):1573-80. PubMed ID: 18940919 [TBL] [Abstract][Full Text] [Related]